LAS VEGAS — Women account for most DOs practicing primary care for the first time ever, a recent report from the American Osteopathic Association, or AOA, shows.
According to the 2026 Osteopathic Medical Profession Report, women account for 50.2% of primary care DOs overall — up from 49.6% last year — and 55.4% of primary care DOs aged younger than 35 years.
Additionally, the number of women DOs younger than age 45 years surpassed 50,000 for the first time, an AOA press release said.
“As more women choose osteopathic medicine and primary care, patients benefit from a broader range of

AI search tools did not always correctly identify the validation status of home BP monitors, according to an abstract presented at the American Heart Association’s Hypertension Scientific Sessions.
“People may unknowingly think a device is validated based on the AI tool’s inaccurate responses,” Anna Soriano, MD, third-year internal medicine resident at the University of Montreal, said in a press release. “Using that device may result in inaccurate blood pressure readings, which could lead to an inappropriate diagnosis or treatment decisions.”
The American Heart Association recently released a

Hidradenitis suppurativa affects approximately 1% of the world’s population, yet patients searching for more information or treatment resources may stumble over how to spell the skin disease with a long and difficult to pronounce name.
Despite being a medically correct term, the words “hidradenitis suppurativa” are usually flagged as a spelling error across iOS and other digital platforms. This can impact how patients, clinicians, researchers and advocates communicate about the disease, according to Shyla Harvin, a medical student at Meritus School of Osteopathic Medicine. The problem inspired

First-line pembrolizumab significantly improved PFS compared with chemotherapy alone for a subgroup of patients with endometrial cancer, according to results of the randomized phase 3 KEYNOTE-093 trial.
Pembrolizumab (Keytruda, Merck) also appeared associated with improved quality of life, findings presented at European Society for Medical Oncology Congress showed.
Importantly, the trial — which included patients with mismatch repair-deficient (dMMR) advanced or recurrent disease — did not compare pembrolizumab monotherapy with the current standard of care, which is chemotherapy plus

NEW ORLEANS — In this video, David A. Eichenbaum, MD, FASRS, of Retina Vitreous Associates of Florida, highlights data from the phase 3 DAYBREAK trial on the use of Zenkuda for the treatment of wet age-related macular degeneration.
In the DAYBREAK clinical trial, presented at the American Academy of Ophthalmology meeting, researchers assessed Zenkuda (tarcocimab tedromer, Kodiak Sciences) and KSI-501 (tabirafusp alfa tedromer, Kodiak Sciences) vs. Eylea (aflibercept, Regeneron) in patients with wet AMD.
Eichenbaum said 54% of patients who received Zenkuda went out as far as 6 months without

Despite one patient death, the safety profile for zolacabtagene autoleucel in a phase 1 study of patients with multiple sclerosis was considered consistent with previous data, according to data presented at MSToronto 2026.
The efficacy of the investigational, autologous CD19-directed chimeric antigen receptor T-cell therapy was promising as well, Jeffrey A. Cohen, MD, professor of neurology and staff physician at the Mellen Center for Multiple Sclerosis, Cleveland Clinic, and colleagues reported.
“Several of our approved MS therapies are monoclonal antibodies that also target B cells, and

Testosterone therapy may help maintain bone mineral density and increase lean mass for teenage boys and young men with Prader-Will syndrome without adverse effects on behavior, according to data from the Netherlands.
Demi J. Trueba‐Timmermans, PhD, researcher in the department of pediatrics, subdivision of endocrinology at Erasmus University Medical Center‐Sophia Children’s Hospital in the Netherlands, and colleagues wrote that symptoms of Prader-Willi syndrome can lead to hypothalamic dysfunction and can cause hypogonadism for boys. They said hypogonadism can lead to boys with Prader-Willi

NASHVILLE, Tenn. — JAK inhibitors are associated with meaningful clinical and endoscopic outcomes compared with TNF inhibitors in patients with ulcerative colitis, according to findings presented at ACG Annual Scientific Meeting.
“Ulcerative [colitis] treatment now includes multiple advanced therapy classes. But in real world practice, patients are not treated like randomized trial participants,” Naveed Chaudhry, DO, an internal medicine resident at Baylor Scott & White Medical Center in Texas, told attendees. “Treatment selection is influenced by prior biologic failure, steroid dependence

PHOENIX — More patients with bronchiectasis and Sjögren’s syndrome vs. only bronchiectasis had gastroesophageal reflux disease, a pulmonary-related hospitalization and Staphylococcus aureus, according to a presentation here.
“Patient with Sjögren’s and bronchiectasis represent a unique population,” Adrienne Strait, MD, pulmonary and critical care medicine fellow at Stanford Medicine, said during her presentation at the CHEST Annual Meeting.
In this study, Strait and colleagues analyzed 71 patients with bronchiectasis and Sjögren’s syndrome and 5,649 patients with bronchiectasis and no

West Virginia reports 41 Salmonella Typhimurium cases and five hospitalizations since early September. Investigators have not identified a common source or linked infections outside the state.